United Kingdom Bronchodilators Market
is anticipated to witness impressive growth during the forecast period. It can
be ascribed to the growing demand for beta-2 agonists because it gives some
health benefits such bronchodilation, rapid symptom relief, prevention of
exercise-induced bronchoconstriction, and maintenance therapy along with the
growing demand for medical device for intake of metered-dose, dry powder, and
nebulizers as daily routine for health benefits. Also, increasing demand for
nutrients and fortified food additives along with growing demand for
pharmaceutical industry additives such as pharmaceutical companies that
manufacture bronchodilator medications experience increased demand for their
products to create a lucrative growth of United Kingdom Bronchodilators during
the forecast period. Acute (sudden) asthma symptoms are quickly relieved or
eliminated by short-acting bronchodilators. They last between 3-6. A rescue
inhaler is another term for a short-acting bronchodilator.
Bronchodilators are often
administered through various inhalation devices such as metered-dose inhalers,
dry powder inhalers, and nebulizers. The increased demand for bronchodilators
correlates with a higher demand for these medical devices, as patients require
appropriate inhalation devices for effective drug delivery. The primary
function of bronchodilators is to relax the smooth muscles lining the airways
(bronchi and bronchioles). By stimulating the beta-2 adrenergic receptors in
the smooth muscles, bronchodilators cause the muscles to relax, resulting in
the dilation or widening of the airways. This allows for improved airflow and
easier breathing. These factors may anticipate in the growth of United Kingdom
Bronchodilators Market.
Increasing Smoking Rates May
Drives the Market
Smoking contributes to the
development of respiratory conditions such as Chronic Obstructive Pulmonary
Disease (COPD) which includes chronic bronchitis and emphysema and the
subsequent need for bronchodilator treatment. In the UK, 6.6 million people
or 13.3% of adults (18 years and older) smoked cigarettes in 2021. around . Smoking
is a major risk factor for respiratory conditions, including Chronic
Obstructive Pulmonary Disease (COPD) and asthma. An increase in smoking rates
can lead to a higher prevalence of these conditions in the population. As a
result, there may be an increased demand for bronchodilators to manage the
symptoms and provide relief to individuals with these respiratory conditions. Smoking
Cigarette is the main cause of Chronic Obstructive Pulmonary Disease (COPD) and
is thought to be responsible for around 9 in every 10 cases. Smoking-related
respiratory diseases often require long-term management and medication to
control symptoms and improve lung function. Bronchodilators are commonly used
as a part of the treatment regimen for these conditions. In the UK, smoking
is one of the leading causes of illness and death. In the UK, smoking causes
over 76,000 annual deaths, and thousands more suffer from debilitating
illnesses. With an increase in smoking rates, there may be a higher demand
for bronchodilators which drives the United Kingdom bronchodilators market. The
NHS provides smoking cessation services to support individuals in quitting
smoking, which is a key risk factor for respiratory conditions. Smoking-related
respiratory diseases impose a significant burden on healthcare systems. The
increased demand for bronchodilators as a result of smoking-related conditions
can contribute to healthcare expenditure, including costs associated with
medication, hospitalizations, and management of related complications which
anticipates in the growth of United Kingdom bronchodilators market.
Increasing Incidence of
Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary
Disease (COPD) is a prevalent respiratory condition in the United Kingdom, with
a substantial number of individuals diagnosed with the disease. After
asthma, COPD is the second most prevalent lung disease in the UK. 4.5% of all
adults over 40 and 2% of the general population, respectively, have Chronic
Obstructive Pulmonary Disease (COPD). The high prevalence of Chronic
Obstructive Pulmonary Disease (COPD) creates a considerable growth of
bronchodilator market in United Kingdom. Chronic Obstructive Pulmonary Disease
(COPD) is a chronic condition that requires long-term maintenance therapy to
control symptoms and improve quality of life. The second-leading cause of
lung disease death and the fifth-leading cause of death in the UK, Chronic
Obstructive Pulmonary Disease (COPD) claims the death of nearly 30,000 people
annually. The mortality rate increased from 2004 to 2012. Long-acting
bronchodilators, often combined with other medications like inhaled
corticosteroids, are commonly used for maintenance therapy. The requirement for
ongoing maintenance therapy contributes to the growth of bronchodilators market
in United Kingdom.
Bronchodilators are crucial for
managing Chronic Obstructive Pulmonary Disease (COPD) symptoms such as
breathlessness, coughing, and wheezing. They help to improve airflow and
relieve bronchial constriction. Additionally, bronchodilators play a role in
preventing exacerbations, which can be severe and require medical intervention.
The need for symptom management and exacerbation prevention drives the growth
of Bronchodilators Market in United Kingdom. The National Health Service (NHS)
in the United Kingdom provides guidelines for the management of COPD,
emphasizing the use of bronchodilators as a key component of treatment. The
guidelines recommend the use of short-acting bronchodilators as rescue
medication and long-acting bronchodilators as maintenance therapy. The NHS has
developed integrated care pathways for COPD, which provide guidance on the
management of COPD across different healthcare settings. The adherence to these
guidelines drives the demand for bronchodilators in the market.
Increase In Ageing Population
As individuals age, the risk of
developing respiratory conditions such as chronic obstructive pulmonary disease
(COPD) and asthma increases. These conditions often require the use of
bronchodilators for symptom management and improved lung function. The higher
prevalence of respiratory conditions in the aging population leads to an
increased demand for bronchodilators. 4.5% of people aged 40+ having COPD
& similarly, around 7.8% of older adults in United Kingdom have Asthma. The
aging population in the UK has experienced increased life expectancy. In
2022, the life expectancy was 81.65 years increased by 0.15% in 2023 which is
now 81.77 years. However, with longer lifespans, there is an increased
likelihood of developing chronic diseases, including respiratory conditions. It
shows that COPD and asthma are major health issues that affect 20% of the
elderly and 13% of adults, respectively. Bronchodilators are commonly
prescribed for long-term management of these conditions in the aging
population, driving the growth of United Kingdom Bronchodilators Market. The
proportion of older individuals in the UK population is increasing. According to
demographic projections, the number of people aged 65 and over is expected to
rise significantly in the coming years. There are more people than ever in
older age groups, according to Census 2021 data. 18.6% of the total population,
or more than 11 million people, were 65 years of age or older. As a result,
there will be a larger pool of individuals who may require bronchodilators to
manage respiratory conditions associated with aging. Aging is associated with
physiological changes in the respiratory system, such as decreased lung
elasticity, reduced lung function, and increased airway resistance. These
age-related changes can lead to respiratory symptoms and the need for
bronchodilators to improve airflow and alleviate breathing difficulties, which
may contribute to the growth of the United Kingdom bronchodilators market.
Recent Development
- In 2020, Astrazenca acquire Alexion pharmaceuticals
in USD60 Million in cash and 2.1243 AstraZeneca American Depositary shares
(ADSs) To encourage future medical innovation, the combined companies will
bring together two patient-centric models of care delivery that are
quickly convergent and have complementary capabilities in immunology,
biologics, genomics, and oligonucleotides.
- In 2023, AstraZeneca acquire Cincor’s a transaction
value of approximately $1.8bn and a 206% premium over CinCor’s closing
market price on 6 January 2023 attentive on developing novel treatments
for unaffected and uncontrolled hypertension as well as chronic kidney
disease.
- In 2020, Novartis AG acquire The Medicine Company
the company to be received USD 85.00 per share to begin a new chapter on
the use of a vaccine-like strategy for treating the biggest cause of death
and disability in the world. It represents a huge advancement in our
efforts to refocus the business, rethink medicine, and alter the course of
human history.
Download Free Sample Report
Market Segmentation
The United Kingdom
Bronchodilators Market can be segmented by Type, Indication, Route of
Administration, End User, and region. Based on Type, the market can be
segmented into Beta-Adrenergic Bronchodilators, Anticholinergic
Bronchodilators, Xanthine Derivatives, and Others. Based on Indication, the
market can be grouped into Asthma, Chronic Obstructive Pulmonary Disease
(COPD), Others. Based on Route of Administration, the market can be segmented
into Oral, Nasal, Injectable.
Market Players
AstraZeneca PLC, Boehringer
Ingelheim GmbH, Novartis AG, Teva Pharmaceutical Industries Ltd.,
Cipla EU Ltd, Sunovion Pharmaceuticals Ltd, GlaxoSmithKline Inc/United Kingdom.
are some of the leading players operating in the United Kingdom bronchodilators
market.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic
Data
|
2018 –
2021
|
|
Estimated
Year
|
2023
|
|
Forecast
Period
|
2024
– 2028
|
|
Quantitative
Units
|
Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028
|
|
Report
Coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments
Covered
|
Type
Indication
Route of Administration
End User
|
|
Regional
scope
|
Scotland,
South-East, London, South-West, Yorkshire & Humberside, and East Midlands
|
|
Key
companies profiled
|
AstraZeneca PLC, Boehringer Ingelheim GmbH, Novartis AG, Teva Pharmaceutical
Industries Ltd., Cipla EU Ltd, Sunovion Pharmaceuticals Ltd, GlaxoSmithKline
Inc/United Kingdom.
|
|
Customization
scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing
and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel through
Email (We can also provide the editable version of the report in PPT/Word
format on special request)
|
Report
Scope:
In
this report, the United Kingdom bronchodilators market has been segmented into
the following categories, in addition to the industry trends which have also
been detailed below:
- United
Kingdom Bronchodilators Market, By Type:
o
Beta-Adrenergic
Bronchodilators
o
Anticholinergic
Bronchodilators
o
Xanthine
Derivatives
o
Others
- United
Kingdom Bronchodilators Market, By Indication:
o
Capsules
o
Tablets
o
Powder
o
Soft
Gels
o
Liquid
- United
Kingdom Bronchodilators Market, By Route of Administration:
o
Oral
o
Parenteral
Inhalational
o
Others
- United
Kingdom Bronchodilators Market, By Region:
o
Scotland
o
South-East
o
London
o
South-East
o
Yorkshire
& Humberside
o
East
Midlands
Competitive
Landscape
Company
Profiles: Detailed
analysis of the major companies present United Kingdom bronchodilators market.
Available
Customizations:
With
the given market data, TechSci Research offers customizations according to a
company’s specific needs. The following customization options are available for
the report:
Company
Information
- Detailed
analysis and profiling of additional market players (up to five).
The
United Kingdom bronchodilators market has an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at
[email protected]